IRIS
Rimassa, Lorenza
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.802
AS - Asia 8.355
EU - Europa 3.450
SA - Sud America 1.691
Continente sconosciuto - Info sul continente non disponibili 562
AF - Africa 354
OC - Oceania 27
AN - Antartide 2
Totale 31.243
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.332
SG - Singapore 5.008
CN - Cina 1.461
BR - Brasile 1.383
IT - Italia 1.283
VN - Vietnam 807
FI - Finlandia 454
IE - Irlanda 335
DE - Germania 318
CA - Canada 275
HK - Hong Kong 251
GB - Regno Unito 229
FR - Francia 220
NG - Nigeria 206
IN - India 178
NL - Olanda 134
BD - Bangladesh 126
AR - Argentina 115
SE - Svezia 88
MX - Messico 85
TR - Turchia 82
IQ - Iraq 62
RU - Federazione Russa 57
JP - Giappone 55
ID - Indonesia 50
EC - Ecuador 47
ZA - Sudafrica 44
CL - Cile 43
CO - Colombia 41
BE - Belgio 40
IL - Israele 38
PL - Polonia 38
ES - Italia 37
UA - Ucraina 36
AT - Austria 34
PK - Pakistan 31
SA - Arabia Saudita 28
UZ - Uzbekistan 25
MA - Marocco 23
AU - Australia 22
VE - Venezuela 22
PH - Filippine 21
JM - Giamaica 20
EG - Egitto 18
LT - Lituania 17
CR - Costa Rica 16
KE - Kenya 16
CZ - Repubblica Ceca 15
PY - Paraguay 15
AZ - Azerbaigian 14
DZ - Algeria 14
HN - Honduras 14
NP - Nepal 14
PT - Portogallo 13
AE - Emirati Arabi Uniti 12
UY - Uruguay 12
IR - Iran 11
SV - El Salvador 11
JO - Giordania 10
KR - Corea 10
TN - Tunisia 10
CH - Svizzera 9
GT - Guatemala 9
KZ - Kazakistan 9
NO - Norvegia 9
PE - Perù 9
BY - Bielorussia 8
EU - Europa 8
MD - Moldavia 8
MY - Malesia 8
EE - Estonia 7
KG - Kirghizistan 7
AL - Albania 6
BG - Bulgaria 6
DO - Repubblica Dominicana 6
ET - Etiopia 6
GR - Grecia 6
HR - Croazia 6
NI - Nicaragua 6
RO - Romania 6
TH - Thailandia 6
TT - Trinidad e Tobago 6
LB - Libano 5
PA - Panama 5
RS - Serbia 5
BA - Bosnia-Erzegovina 4
BB - Barbados 4
HU - Ungheria 4
LV - Lettonia 4
OM - Oman 4
SK - Slovacchia (Repubblica Slovacca) 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AO - Angola 3
BH - Bahrain 3
BO - Bolivia 3
DK - Danimarca 3
KH - Cambogia 3
ML - Mali 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
Totale 30.643
Salva come PNG Salva come JPEG
Città #
Singapore 2.184
Dallas 1.806
Wilmington 1.301
Chandler 1.287
Ashburn 1.018
San Jose 922
The Dalles 632
Shanghai 567
Milan 541
San Mateo 477
Council Bluffs 470
Helsinki 454
New York 422
Ann Arbor 394
Beijing 374
Dublin 333
Santa Clara 308
Ho Chi Minh City 286
Princeton 282
Lawrence 253
Los Angeles 249
Boardman 244
Leawood 232
Hong Kong 226
Benin City 205
Rome 200
Hanoi 179
Paris 146
Phoenix 131
Buffalo 126
Amsterdam 110
Fairfield 110
Woodbridge 109
São Paulo 104
Toronto 103
London 88
Chicago 79
Columbus 77
Seattle 71
Naples 56
San Diego 56
Brooklyn 51
Orem 47
Montreal 46
Figino 45
Rio de Janeiro 42
Charlotte 40
Atlanta 39
Kocaeli 39
Da Nang 37
Miami 37
Tokyo 37
Belo Horizonte 36
Brussels 36
Haiphong 36
Houston 36
Boston 35
Brasília 35
Falkenstein 35
Mexico City 35
Queens 34
Chennai 33
Norwalk 33
Pune 32
Abbiategrasso 31
Las Vegas 31
Munich 31
Redwood City 31
San Francisco 31
Warsaw 31
Philadelphia 30
Turin 29
Assago 28
North Bergen 27
Salvador 27
Milwaukee 25
The Bronx 25
Denver 23
Tashkent 23
Baghdad 22
Curitiba 22
Manchester 22
Pittsburgh 22
Porto Alegre 21
St Louis 21
Frankfurt am Main 20
Hải Dương 20
Dhaka 19
Florence 19
Guayaquil 19
Johannesburg 19
Sacramento 19
Campinas 18
Pasadena 17
Washington 17
Cincinnati 16
Moscow 16
Redmond 16
Bogotá 15
Guarulhos 15
Totale 18.906
Salva come PNG Salva come JPEG
Nome #
Prognostic Factors and Survival Outcomes in Resected Biliary Tract Cancers: A Multicenter Retrospective Analysis 319
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment 277
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 207
Liver transplantation in a patient with metastatic hepatocellular carcinoma after downstaging with single-agent immunotherapy: the first case report 180
An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab 174
18F-FDG PET and CT scan in the pre-operative evaluation of colorectal liver metastases treated with chemotherapy 168
18F-FDG pet does not improve contrast enhanced CT scan sensitivity in the evaluation of liver metastases after chemotherapy 163
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 159
5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors 156
Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era 149
Tumor-derived prostaglandin E2 promotes p50 NF-κB-dependent differentiation of monocytic MDSC 147
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 146
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer 144
Tivantinib for hepatocellular carcinoma 141
Metastasis of hepatocellular carcinoma to the heart: A case report and review of the literature 137
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 137
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer 135
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 129
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 128
Tumor-associated macrophages and response to 5-flourouracil adjuvant therapy in stage III colorectal cancer 128
Biomarkers in Hepatocellular Carcinoma-Letter 127
Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer 127
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 127
Can SBRT improve the prognosis of unresectable pancreatic cancer? Clinical results on 106 patients 125
Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy 123
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 122
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 121
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 121
COVID-19 and liver cancer clinical trials: not everything is lost 120
Adrenal metastases from adenocarcinoma of the esophagogastric junction: adrenalectomy and long-term survival. 120
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 120
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 119
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 117
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 115
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 115
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial 114
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 113
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 112
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 112
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 111
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 111
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole 109
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 109
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients 109
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma 107
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma 106
Antiangiogenic drugs currently used for colorectal cancer: What other pathways can we target to prolong responses? 105
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer 105
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 105
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 105
Long-term outcomes after pancreatoduodenectomy for ampullary cancer: The influence of the histological subtypes and comparison with the other periampullary neoplasms 105
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 104
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 104
Risk of Cancer in Inflammatory Bowel Diseases: Umbrella Review and Reanalysis of Meta-analyses 103
Medical Oncologists must get more involved in systemic treatment of Hepatocellular Carcinoma 103
Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. 103
Cabozantinib for the treatment of hepatocellular carcinoma 102
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up 102
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 102
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98 101
High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models 101
KRAS mutation in lung metastases from colorectal cancer : Prognostic implications 101
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma 100
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 100
Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer 100
Clinical implications of immunohistochemical assessment of somatostatin receptors subtype 2 and 5 in the diagnostic and therapeutic management of gastro-entero-pancreatic neuroendocrine tumours 100
Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer 100
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 99
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 99
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 99
From barriers to solutions: an expert-based algorithm for cholangiocarcinoma and other biliary tract cancers testing in the Era of precision oncology 99
Characterisation of the immune-related transcriptome in resected biliary tract cancers 99
Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers 99
Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib 98
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine 98
Irinotecan and raltitrexed: an active combination in advanced colorectal cancer 98
Prognostic value of the immune-related transcriptome in biliary tract cancers 98
FOLFOX/CAPOX in stage II–III colon cancer: efficacy results of the Italian Three Or Six Colon Adjuvant trial (TOSCA) 98
Reply to Y. Pointreau et al 98
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis 98
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab 97
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial 97
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 97
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 96
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 96
Chemotherapy with mitomycin c and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin 96
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 96
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 95
Neuroendocrine differentiation in solid tumors 95
SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. 95
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 95
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma 95
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study 94
Etiology of hepatocellular carcinoma may influence the pattern of progression under atezolizumab-bevacizumab 94
Shaping the landscape of immune oncology in hepatocellular carcinoma 93
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 93
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 92
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial 92
Phase III trial comparing 3 to 6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial 92
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 92
Totale 11.679
Salva come PNG Salva come JPEG
Categoria #
all - tutte 187.813
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 187.813
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.380 0 0 0 316 28 33 70 219 136 211 270 97
2022/20233.786 563 174 342 440 302 293 35 310 675 355 257 40
2023/20242.440 161 251 455 89 76 341 161 127 36 53 278 412
2024/20253.714 121 62 29 57 75 432 284 337 580 794 424 519
2025/202612.353 1.462 1.455 1.081 1.192 339 527 2.794 506 535 768 675 1.019
2026/20274.908 1.359 961 1.913 675 0 0 0 0 0 0 0 0
Totale 31.243